ArticleCureus2025
Dose-Summation-Guided Re-irradiation Planning for Brain Metastases: Cross-Platform Verification Between Brainlab Elements and GammaPlan.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a practical, cross-platform workflow for cumulative-dose-aware re-irradiation in brain metastases. Before RT-DOSE is imported across planning systems (Brainlab Elements and/or GammaPlan), previously irradiated foci are treated prospectively as organs-at-risk during optimization, and the summed dose is visualized to avoid hotspots while preserving coverage. In a verification case planned without dose summation, a non-target previously irradiated focus ultimately developed radiation necrosis; post-hoc summation showed that explicit constraints could have reduced cumulative exposure. In a second case prospectively planned with summation, target coverage was maintained while decreasing the unintended dose to a non-target previously treated focus, with subsequent control and no new toxicity. This cross-platform approach is feasible and clinically actionable for balancing efficacy and safety during repeat stereotactic radiosurgery near prior high-dose regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.